We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effectiveness of Cow's Milk Immune Globulin in the Treatment of AIDS-Related Diarrhea

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00002264
First Posted: August 31, 2001
Last Update Posted: December 9, 2005
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
NIH AIDS Clinical Trials Information Service
November 2, 1999
August 31, 2001
December 9, 2005
Not Provided
Not Provided
Not Provided
Not Provided
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
The Effectiveness of Cow's Milk Immune Globulin in the Treatment of AIDS-Related Diarrhea
Efficacy of Cow's Milk Immune Globulin in the Treatment of Chronic Intestinal Cryptosporidiosis in Patients With AIDS
To examine the efficacy of cow's milk immune globulin in the treatment of diarrhea due to chronic intestinal cryptosporidiosis in patients with AIDS. The secondary end points of the study involve functional improvement which will be determined from nutritional and absorption studies.
Not Provided
Interventional
Not Provided
Primary Purpose: Treatment
  • Cryptosporidiosis
  • HIV Infections
Drug: Cryptosporidium Immune Whey Protein Concentrate (Bovine)
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
Not Provided
Not Provided

Inclusion Criteria

Patients must have:

  • Diagnosis of diarrhea associated with intestinal cryptosporidiosis.

Exclusion Criteria

Co-existing Condition:

Patients with the following conditions or symptoms are excluded:

  • Survival time projected to be < 9 weeks.
  • Inability to tolerate any oral intake.
  • Known allergy or intolerance to milk products.
  • Organic mental syndrome precluding informed consent or following directions.

Patients with the following are excluded:

  • Survival time projected to be < 9 weeks.
  • Inability to tolerate any oral intake.
  • Known allergy or intolerance to milk products.
  • Organic mental syndrome precluding informed consent or following directions.
Sexes Eligible for Study: All
12 Years and older   (Child, Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00002264
068A
WPC-S123
Not Provided
Not Provided
Not Provided
Not Provided
Stolle Milk Biologic International
Not Provided
Not Provided
NIH AIDS Clinical Trials Information Service
November 1999

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP